Denali Therapeutics Competitors, Revenue, Alternatives and Pricing

Claim your profile

Overview

Location:
Total Funding:$597M
Industry:Biotech
Founded:2015
Lead Investor(s):Genentech

Industry Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • Denali Therapeutics's estimated annual revenue is currently $129M per year.
  • Denali Therapeutics received $130.0M in venture funding in August 2016.
  • Denali Therapeutics's estimated revenue per employee is $440,273
  • Denali Therapeutics's total funding is $597M.

Employee Data

  • Denali Therapeutics has 293 Employees.
  • Denali Therapeutics grew their employee count by 9% last year.
  • Denali Therapeutics currently has 24 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingOnline ReviewPricing
DiaCarta
$7M4510%N/A-N/A
Geron Corporati...
N/A205N/AN/A-N/A
Rigel Pharmaceu...
$46.8M3024%N/A-N/A
Althea Technolo...
$22.3M144N/AN/A-N/A
INOVA Diagnosti...
$44.3M286N/AN/A-N/A
10X Genomics
$101.2M65346%N/A-N/A
ProTrials Resea...
$33.3M2153%N/A-N/A
Advanced Cell D...
$28.7M1858%N/A-N/A
The J. Craig Ve...
$39.4M254N/AN/A-N/A
CellMax Life
$6.5M4214%N/A-N/A
Missing a competitor? Contribute!?
Submit

Denali Therapeutics Inc. (Denali) is a biotechnology company focused on the discovery and development of therapies for patients with neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, ALS and others. Denali was founded by scientists, industry experts and investors who share the vision that recent scientific insights into the genetic causes and biological processes underlying neurodegenerative disease, together with new translational medicine tools, offer an unprecedented opportunity to discover and develop effective medicines. Denali is rigorously pursuing a science-driven approach to translational medicine and clinical development. Founding investors include Fidelity Biosciences, ARCH Venture Partners, Flagship Ventures and the Alaska Permanent Fund (represented by Crestline Investors).

keywords:Biotechnology,Cleantech,Healthcare,Medical Diagnostics,Pharmaceuticals,Wind Power

293

Number of Employees

$129M

Revenue (est)

24

Current Jobs

9%

Employee Growth %

$597M

Total Funding

N/A

Valuation

N/A

Accelerator

B2B

Type

Denali Therapeutics News

09/07/2019 - Denali Therapeutics Announces First Patient Dosed in Phase ...

Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL151 for Parkinson's Disease and Launch of Its Engage ...

09/08/2019 - GSA Capital Partners LLP Boosts Holdings in Denali ...

GSA Capital Partners LLP increased its holdings in Denali Therapeutics Inc (NASDAQ:DNLI) by 174.3% in the second quarter, according to its ...

09/04/2019 - Denali Therapeutics (DNLI) Reports First Patient Dosing in ...

Denali Therapeutics Inc. (NASDAQ: DNLI) today announced initiation of dosing in a Phase 1b clinical study of LRRK2 inhibitor DNL151 in ...

Denali Therapeutics Funding

DateAmountRoundLead InvestorsReference
2015-05-15$217.0MAArticle
2016-08-26$130.0MBGenentechArticle

Denali Therapeutics Executive Hires

DateNameTitleReference
2015-07-23Carole HoChief Medical Officer/Head of DevelopmentArticle
2018-08-08Dana AndersenChief Technical and Manufacturing OfficerArticle